Currently Viewing:
American Society of Hematology
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18, 2018
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17, 2018
Dr Derek Raghavan Addresses the Concept of "Cookbook Medicine"
April 09, 2018
Dr Nina Shah Outlines New Treatments Being Studied for Multiple Myeloma
April 07, 2018
Dr Thomas LeBlanc: How to Increase Palliative Care Among Patients With Blood Cancer
April 02, 2018
Dr Thomas LeBlanc on Improving End-of-Life Outcomes for Patients With Blood Cancer
March 21, 2018
Dr Thomas LeBlanc: Patients With Blood Cancer and Palliative Care
March 10, 2018
Currently Reading
Julie Wolfson: Supporting AYAs Before and After Treatment
January 14, 2018
Dr Nina Shah on the Impact of New Treatments for Multiple Myeloma
December 29, 2017
Dr Stephen Schuster on Institution Commitments to Deliver CAR T Therapies
December 28, 2017
Dr Shannon Maude Discusses Side Effects of CAR T Therapies
December 25, 2017
Diagnosing Congenital Neutropenia
December 23, 2017
Dr Derek Raghavan: Ensuring Guidelines Are Implemented and Followed
December 22, 2017
New Drug Approvals in Leukemia and Lymphoma Presented at ASH 2017
December 18, 2017
Care Utilization Patterns in Sickle Cell Disease: Managing Pain and Care Transitions in AYAs
December 18, 2017
Diagnosing Non-Chemotherapy Drug-Induced Neutropenia
December 16, 2017
Dr Stephen Schuster Outlines CAR T Results Seen in Leukemia, Lymphoma, and Myeloma
December 12, 2017
New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study
December 12, 2017
Dr Julie Wolfson Highlights Different Outcomes in AYAs With ALL Compared With Children
December 12, 2017

Julie Wolfson: Supporting AYAs Before and After Treatment

The challenges that adolescents and young adults face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine.
 


The challenges that adolescents and young adults (AYAs) face before and after treatment are all unique to an individual patient, according to Julie Wolfson, MD, of the University of Alabama at Birmingham School of Medicine, who presented findings on the different outcomes between children and AYAs with acute lymphoblastic leukemia (ALL) at the 59th American Society of Hematology Annual Meeting.

Transcript

How does social support play a role in outcomes among adolescents and young adults with ALL?

It’s not something that we looked at specifically in terms of social support but I think that it really is important when we look at the fact we saw that the duration of treatment, the length of maintenance treatment is really important. We know that these patients are in a really volatile time in their lives. Everyone comes in with a lot of important things happening in their life and that has been disrupted and so others have shown how important social support is and we’ve shown the importance of the duration of treatment. So together I think that just means that making sure we are paying attention to the social needs of these patients is crucial.

What are the unique challenges facing AYAs after treatment?

There are so many challenges that these patients face that are unique and I think that people are really working hard to try to figure out what we can do to help them. But I think the minute they walk into the door, thinking of them as a unique group of patients is the first thing we can do and just recognizing that their lives have been disrupted in a way that younger patients and older patients don’t experience and trying to understand that unique patient’s needs.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!